Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H14F3NO2.ClH |
Molecular Weight | 285.691 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC(CCN)=C(OC)C=C1C(F)(F)F
InChI
InChIKey=PKDYDXSVFVEQGA-UHFFFAOYSA-N
InChI=1S/C11H14F3NO2.ClH/c1-16-9-6-8(11(12,13)14)10(17-2)5-7(9)3-4-15;/h5-6H,3-4,15H2,1-2H3;1H
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22374819Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7996545 | https://www.ncbi.nlm.nih.gov/pubmed/20481515 | https://www.ncbi.nlm.nih.gov/pubmed/18666267
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22374819
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7996545 | https://www.ncbi.nlm.nih.gov/pubmed/20481515 | https://www.ncbi.nlm.nih.gov/pubmed/18666267
2,5-Dimethoxy-4-trifluoromethylamphetamine (DOTFM) is the alpha-methylated analogue of 2C-TFM, a psychedelic drug of the phenethylamine and amphetamine chemical classes. 2,5-Dimethoxy-4-trifluoromethylamphetamine acts as an nanomolar agonist at the 5HT2A and 5HT2C receptors and possess hallucinogenic effects in humans.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7996545 |
33.0 nM [Ki] | ||
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7996545 |
2225.0 nM [Ki] | ||
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11300881 |
3.78 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22374819
0.3 mg as a single dose
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7996545
The frontal cortex or hippocampal brain regions from 20-40 rats were pooled and homogenized in 4 or 8 volumes of 0.32 M sucrose for frontal cortex or hippocampus, respectively. The homogenates were centrifuged at 36000g for 10 min, and the resulting pellets were resuspended in the same volume of sucrose. All experiments were performed with triplicate determinations using the appropriate buffer to which 200-400 mkg of protein was added, giving a final volume of 1 mL. The tubes were allowed to equilibrate for 15 min at 37 C before filtering through Whatman GF/C filters using a cell harvester followed by two 5 mL washes using icecold Tris buffer. Specific binding was defined as that displaceable with 10 mkM cinanserin in both the [3H]ketanserin and [125I]DOI binding study and with 10 mkM 5-HT in the [3H]-8-OH-DPAT binding study. Filters were air-dried and placed into scintillation vials with 10 mL of Ecolite scintillation cocktail and allowed to sit overnight before counting at an efficiency of 37% for tritium and directly counted in a y counter for [125I]-labeled ligand at an efficiency of 79.4%.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Y7EUD382AD
Created by
admin on Sat Dec 16 09:52:40 GMT 2023 , Edited by admin on Sat Dec 16 09:52:40 GMT 2023
|
PRIMARY | |||
|
159277-13-1
Created by
admin on Sat Dec 16 09:52:40 GMT 2023 , Edited by admin on Sat Dec 16 09:52:40 GMT 2023
|
PRIMARY | |||
|
76963284
Created by
admin on Sat Dec 16 09:52:40 GMT 2023 , Edited by admin on Sat Dec 16 09:52:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD